key: cord-0332643-mc2af467
authors: Teh, J. S. K.; Coussement, J.; Neoh, Z. C. F.; Spelman, T.; Lazarakis, S.; Slavin, M. A.; Teh, B. W.
title: Immunogenicity of COVID-19 vaccines in patients with haematological malignancy: A systematic review and meta-analysis
date: 2021-11-08
journal: nan
DOI: 10.1101/2021.11.06.21265967
sha: f14ff085a356cec7057ed3ff49f3350f0031c902
doc_id: 332643
cord_uid: mc2af467

The objectives of this study were to assess the immunogenicity and safety of COVID-19 vaccines in patients with haematological malignancy. A systematic review and meta-analysis of clinical studies of immune responses to COVID-19 vaccination stratified by underlying malignancy and published from 1 January 2021 to 31 August 2021 was conducted using MEDLINE, EMBASE and CENTRAL. Primary outcome was the rate of seropositivity following 2 doses of COVID-19 vaccine with rates of seropositivity following 1 dose, rates of positive neutralising antibody (nAb), cellular responses and adverse events as secondary outcomes. Rates were pooled from single arm studies while rates of seropositivity were compared against the rate in healthy controls for comparator studies using a random effects model and expressed as a pooled odds ratio with 95% confidence intervals. Forty-four studies (16 mixed group, 28 disease specific) with 7064 patients were included in the analysis (2331 following first dose, 4733 following second dose). Overall seropositivity rates were 61-67% following 2 doses and 37-51% following 1 dose of COVID-19 vaccine. The lowest seropositivity rate was 51% in CLL patients and was highest in patients with acute leukaemia (93%). Following 1 dose, nAb and cellular response rates were 18-63% and 33-86% respectively. Active treatment, ongoing or recent treatment with targeted and CD-20 monoclonal antibody therapies within 12 months was associated with poor COVID-19 vaccine immune responses. New approaches to prevention are urgently required to reduce COVID-19 infection morbidity and mortality in high-risk patient groups that respond poorly to COVID-19 vaccination.

The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted in global mortality of over 3 million deaths. SARS-CoV-2 is likely to remain an endemic viral pathogen, with new variants continuously emerging 1 . There is a significant burden of morbidity and mortality from COVID-19 infection in haematology patients. Over 80% of patients require hospitalisation and up to 50% present with severe disease [2] [3] [4] [5] . Approximately 15% require intensive care unit admission and mortality rates are high at 30-40% depending on underlying disease [2] [3] [4] [5] [6] [7] . Poor control of infection due to immune compromise lead to emergence of new variants which further complicate management 8 .

Vaccination is an effective public health measure to reduce risk of infection and severe complications from COVID-19 9 . However, patients with haematological malignancies were excluded from the pivotal trials which preceeded regulatory approvals of the currently recommended COVID-19 vaccines 10-13 . Understanding the impact of COVID-19 vaccines on cancer patients is critical as social distancing restrictions are being eased in countries with relatively high rates of vaccination coverage 14 . Assessing immune response post-vaccination is the basis of many vaccination studies in patients with haematological malignancy and is often utilised as a surrogate marker of vaccine efficacy [15] [16] [17] . These studies are the basis for vaccination recommendations contained within international guidelines 18, 19 . Therefore, this study was conducted to systematically review available data on the humoral and cellular immune responses to COVID-19 vaccination in patients with haematological malignancy to build the evidence base for its utility.

The main objective of this systematic review was to assess the immunogenicity (i.e., vaccineinduced immune response) of COVID-19 vaccines in patients with haematological malignancy, stratified by underlying disease type. The secondary objective was to assess the safety of COVID-19 vaccines in the same patient groups.

This systematic review was preregistered with PROSPERO (CRD42021276851), and conducted in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 20 .

Studies eligible for inclusion into the systematic review were those that investigated the vaccine-induced immunity in patients with haematological malignancy who received at least one dose of COVID-19 vaccine. Randomised controlled trials (RCTs), quasi-RCTs and observational studies were eligible for inclusion. All types of observational studies were included (including prospective and retrospective studies, and studies with or without a control group). This systematic review evaluated all studies that reported on at least one of the following haematology patient groups: 4 1) All patients with haematological malignancy 2) Patients with multiple myeloma (MM) 3) Patients with chronic lymphocytic leukaemia (CLL) 4) Patients with lymphoma; Hodgkins (HL) and non-Hodgkins lymphoma (NHL) 5) Patients with acute myeloid or lymphocytic leukaemia (AML, ALL) 6) Patients undergoing or who have completed haematopoietic stem cell transplantation (HCT) and chimeric antigen T-cell receptor (CAR-T) therapy 7) Patients with myeloproliferative neoplasm (MPN) and chronic myeloid leukaemia (CML)

The type of intervention was the use of one or two doses of COVID-19 vaccine (of any type). Immune response to COVID-19 vaccination included humoral and cellular immune responses.

For the purpose of this systematic review, humoral response consists of seropositivity which was defined by the SARS-CoV-2 spike/receptor binding domain specific IgG level above the threshold of detection for the assay utilised in each study. Rate of positive neutralising antibody response (nAb) was defined by SARS-CoV-2 specific nAb level above the threshold established by the dedicated neutralisation assay utilised in each study. A positive cellular response was defined by the appropriate increase in frequency of SARS-CoV-2 specific CD4+/CD8+ T cells following vaccination according to assays utilised. Where available, the immune response for each malignant patient group was compared to a control group. If there was no comparator group, the immune response for each haematology patient group was described and summarised.

The primary outcome was rates of seropositivity following two doses of COVID-19 vaccine stratified by disease groups while secondary outcome measures were the rates of seropositivity following one dose of vaccine, rates of positive nAb response following one and two doses of COVID-19 vaccine, rates of positive cellular response following one and two doses of COVID-19 vaccine and rates of systemic and/or local adverse events (whichever rate was higher) following two doses of COVID-19 vaccine.

Search strategy Electronic searching Literature searches were conducted by an experienced research librarian (SL) using the following databases to identify relevant articles: Ovid Medline, EMBASE and Cochrane CENTRAL from 1 January 2020 to 31 August 2021 and for articles in English only. A combination of subjects and keyword terms encompassing haematologic cancers, COVID-19 and vaccines and all their associated terms was used for the search. The terms used included: haematological neoplasms, leukemia, lymphoma, multiple myeloma, myeloproliferative 5 disorders, myelodysplastic-myeloproliferative diseases, stem cell transplantation, bone marrow transplantation, chimeric antigen receptor therapy, COVID-19, SARS-CoV-2, vaccines, vaccination, immunise, immunisation, BNT162b2, CHAdOx1, AZD 1222, mRNA-1273, Ad26, Ad5, NVX-CoV2373. All word variations were searched and Medical subject headings were exploded. The detailed search strategy is summarised in Supplementary Appendix.

Studies were excluded from the systematic review if they did not measure or report immunogenicity after COVID-19 vaccination, if insufficient details were reported for the haematology patient groups in mixed group studies, if there were less than 10 patients including case reports, if data was exclusive to paediatric patients less than 18 years of age or animal studies. Studies that were not peer reviewed and/or published such as pre-prints, abstracts and government reports were excluded. Review articles and other publications without original data such as expert opinions, editorials and consensus statements were also excluded.

Study eligibility was assessed by two independent reviewers (BT, JT), and Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) was used to screen titles, abstracts, and full texts. Irrelevant reports were discarded, and the full texts of the other reports were accessed. Disagreements between the two main reviewers with respect to study eligibility were resolved by discussion, or via consultation with a third author.

For studies fulfilling inclusion criteria, data were extracted manually and independently by authors (JT, JC, BT) using a predefined data extraction form. Extracted data elements included study design (enrolment, follow up period, randomisation/allocation, laboratory analysis, predefined outcomes, adjusted analysis, funding source), participant information (inclusion criteria, number of participants, characteristics, disease, treatment), intervention (vaccine type, dose, schedule, comparator group) and outcomes (definitions, timing, adverse events).

Two review authors (ZN, MS) independently assessed the risk of bias of each cohort study using the Newcastle-Ottawa Scale 21 . Each included study was assessed based on three domains: (1) the selection of the study groups, (2) the comparability of the study groups, and (3) the ascertainment of outcome of interest. The rating system proposed by Sharmin et al 22 was adopted with a good quality study scoring 3 or 4 stars in the selection domain, 1 or 2 stars in comparability domain, and 2 or 3 stars in the outcome domain. For single arm studies, a good quality study would score 3 stars in selection domain, and 2 or 3 stars in outcome domain.

6

For each study, the number of patients achieving seropositivity and the total number of patients receiving vaccination was extracted and expressed as a proportion. For the metaanalysis, rate of response following Ad26 vaccine was analysed at the same time point and therefore summarised as part of a two-vaccine dose response. For each haematology disease group, the proportions from each study were pooled and expressed as an overall proportion (response rate) with 95% confidence intervals (95% CI) utilising inverse variance/generalised mixed modelling.

For each study with a control group, the number of patients with seropositivity in each group and the total number of patients receiving vaccination were extracted, expressed as a proportion with 95% CI and compared against each other. A meta-analysis was performed if there were two or more studies identified with a similar population and sufficient data for the outcomes of interest. The rate of seropositivity as a dichotomous outcome of interest across studies was summarised using a random effects model and expressed as a pooled odds ratio with 95% CI. Analysis was performed using metaprop function on R 4.1.1 (R foundation for Statistical Computing, Vienna).

Clinical and methodological heterogeneity between included studies was assessed by comparing the key patient factors and study factors (vaccine type, type of assay utilised, threshold for positive response, duration of follow up). Statistical heterogeneity was assessed by using the I 2 statistic and Chi 2 with a p value £ 0.05 considered significant for the presence of heterogeneity.

If available, reason(s) for missing data were outlined. Due to time limitations, further information was not sought from the original author/corresponding author(s).

Pre-planned subgroup analysis was performed to evaluate impact of active treatment (versus no active treatment), anti-CD-20 therapy in the last 12 months including current CD-20 therapy (versus anti-CD-20 therapy 12 or more months ago), targeted therapy ( Table 1 .

Overall 23 studies (52%) were evaluated to be good or fair quality (Good = 11, Fair = 12) with low risk of bias whilst the remaining 21 studies were rated as poor quality (high risk of bias) predominantly due to lack of details regarding patient selection, demonstration that outcome of interest was not present at start of study, comparability of cohorts (design or analysis) and follow up duration. Risk of bias and quality assessment of studies are summarised in Supplementary Table 1 .

There were 44 studies measuring humoral immune responses in patients with haematological malignancy. The majority of studies evaluated the use of BNT162b2 (Tozinameran, Pfizer) and utilised SARS-CoV-2 spike specific IgG levels above the threshold of detection (seropositivity). Several studies attempted to establish potential thresholds for clinical protection with higher antibody levels than the seropositivity threshold utilised. Table 4 ), pooled seropositivity rates were 52-55% following 2 doses and 33% following 1 dose of COVID-19 vaccine. Compared to healthy cohort, ORs for achieving seropositivity were 0.01 to 0.02 for lymphoma patients (Table 2 ).

Patients following HCT and CAR-T A total of 6 studies included in this review reported on immune responses following HCT and CAR-T therapy (Supplementary Table 5 ). Two studies involved allogeneic HCT (alloHCT) patients 57,58 , one included alloHCT and CAR-T treated patients 59 and the other study included all HCT and CAR-T patients 60 . Two studies were larger studies of haematology patients with subset of HCT and CAR-T patients 28,29 . 422 patients were included consisting of 401 patients who had 2 doses and the remainder received 1 dose of COVID-19 vaccine. Pooled seropositivity rate was 61% following 2 COVID-19 vaccine doses. For patients following alloHCT the rate was 74% while following CAR-T, it was 31%. In a single study with a healthy control cohort, seropositivity rate was 81% in autologous HCT patients compared to 99% 29 . In the only study of immune response following one COVID-19 vaccine dose, rate of seropositivity was 38% in alloHCT patients 57 .

Patients with acute leukaemia and MDS There were no dedicated studies of COVID-19 vaccination in patients with acute leukaemia. A subset of 126 patients with acute leukaemia and MDS were reported in 6 studies (Supplementary Table 6 ) and seropositivity rate was 93% following 2 doses of COVID-19 vaccine. In a single study, the seropositivity rate was 80% in acute leukaemia, 94% in MDS patients compared to 99% in the control group 29 . No patients with acute leukaemia mounted an immune response following a single vaccine dose compared to 86% of controls 34 . Rates of neutralising antibody, cellular response and adverse events Only 6 studies (14%) reported nAb responses and 4 studies (9%) reported cellular responses.

In the only study on nAb following 2 COVID-19 vaccine doses, 71% of myeloma patients achieved a positive nAb response compared to 90% of the control group 45 . Following 1 dose of COVID-19 vaccine, the overall pooled rate of a positive nAb response was 18% for all patients with haematological malignancy ( Table 3 ). The pooled rate of 2 single arm studies of MPN patients was 63%. For cellular responses following COVID-19 vaccination, the rate of achieving a positive response was 40-75% for all patients following 2 doses and 33-86% following a single dose. In a single study of alloHCT and CAR-T patients, cellular response rates were 19% and 50% respectively following 2 doses 59 . In MPN patients, this rate was 86% following one dose 64,65 . In 10 studies (22%) the rate of at least one systemic or local adverse event was reported. Overall, the pooled rate of at least one adverse event was 36% following 2 doses and 39% following a single dose (Table 3) .

Study characteristics and outcomes of studies included in subgroup analyses are summarised in Supplementary Tables 8-12 . Vaccination with 2 vaccine doses during active therapy was associated with seropositivity rates of 28% compared to 62% off therapy with OR 0.21 (95% CI 0.06-0.67, p=0.02). Lower seropositivity rates (19% vs. 61%) were reported with vaccination during or within 12 months of CD-20 antibody therapy compared to vaccination 12 or more months after completion of therapy. Use of targeted therapy was associated with a pooled seropositivity rate of 35% following 2 doses of COVID-19 vaccine. Seropositivity rates did not differ by timing of vaccination in relation to HCT (66% vs 68%) or vaccine type (62% vs 68%, 95% vs 91%) following 1 or 2 doses. Table 4 summarises the seropositivity rates by each subgroup analysed.

Exclusion of studies that were assessed as poor quality and high risk of bias did not alter the pooled seropositivity rates (single arm) but in comparator studies, OR was now 0.31 (95%CI 0.13-0.78, p=0.03) following 1 dose instead of 0.10 (Supplementary Table 13 ).

In this systematic review and meta-analysis of over 7000 patients with haematological malignancy, rate of seropositivity was 61-67% following 2 doses and 37-51% following 1 dose of COVID-19 vaccination. Compared to age matched and non-matched healthy controls primarily healthcare workers, odds of achieving seropositivity were significantly lower by 95% and 90% following 2 doses and 1 dose of COVID-19 vaccination respectively. Statistical heterogeneity was substantial at over 80% and studies were also clinically heterogenous due 10 to the variety of underlying haematological malignancies, lack of standardised laboratory platforms by which to measure immune response to vaccination and variable follow up periods. Reassuringly, reported rates of at least one adverse effect following vaccination were lower at 36% compared to rates reported in clinical trials of the general population 10,13 .

Amongst different haematological malignancies, pooled seropositivity rates following 2 doses were highest at close to 90% in patients with acute leukaemia, MDS and MPN and the lowest at 51% in CLL patients. Patients with CLL respond poorly to vaccination, especially to new or novel antigens compared to recall antigens from previous infections or vaccination 67 . Poor response is compounded by use of B-cell depleting and targeted therapies such as CD-20 monoclonal antibodies and BTKi 67 . Immune response to other vaccines including seasonal influenza vaccine is negatively impacted by these therapies and the poor response persists for at least 6 to 12 months following cessation of therapy 68 .

A similar negative impact of treatment on COVID-19 vaccine responses was noted in subgroup analysis of published studies. Rates of seropositivity were lower in the setting of active treatment (28%) and the lowest response rates of 19%, 35% and 31% were reported in the setting of current or CD-20 monoclonal antibody therapy within 12 months, targeted therapies and following CAR-T cell therapy. Seropositivity rates were two to three times higher at 61 and 62%% when patients were vaccinated when not on active therapy or 12 or more months following completion of CD-20 monoclonal antibody respectively.

Unvaccinated CLL patients have a high burden of morbidity from COVID-19 infection with close to 90% of patients requiring hospital admission, 35% intensive care unit admission and mortality rates 4 . Yet, CLL patients have poor humoral responses to vaccination at 18% following 1 dose and 51% following 2 doses. In CLL patients, immune suppression from underlying disease and ongoing treatments such as anti-CD20 monoclonal antibodies and BTKi continue to pose a risk for SARS-CoV-2 infection and concurrently limit protective responses from vaccination. Although vaccination remains highly recommended, new strategies are required to further improve immune responses in this high-risk patient population. In other immune compromised groups, the use of an additional dose of COVID-19 vaccine improved serological response rates by 37% and use of heterologous vaccination schedules (mixing vaccine types) appear promising 69-71 . International health bodies now recommend third COVID-19 vaccine doses in immune compromised patients including haematological malignancy 72,73 . Heterologous prime-boost or use of high dose vaccine formulations have been utilised in randomised trials of seasonal influenza vaccination in haematology and HCT patient with mixed success 17,74 . In addition, other preventative approaches such as the use of anti-SARS-CoV-2 monoclonal antibody therapy as pre exposure (NCT04625725) and post exposure prophylaxis require further evaluation in vulnerable patient groups who respond poorly to vaccination 75 .

Serological responses are classically utilised as surrogate end points for clinical efficacy in clinical trials of vaccination in patients with haematological malignancy 15-17 . Serological thresholds for protection (seroprotection) following vaccination have been established for infections such as seasonal influenza 17 . In the majority of studies included in this review, however, the outcome of interest was seropositivity as defined by antibody levels above the detection threshold. This is not equivalent to seroprotection as thresholds have not been All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted November 8, 2021. standardised nor established across the variety of commercial and research platforms utilised by these studies. Some authors such as Redjoul, Stampfer and Malard et. al. have attempted to define serological thresholds that correlate with nAb and clinical protection 33,43,58 . Unsurprisingly a lower proportion of patients (by 20-35% compared to pooled rates) achieve these higher antibody thresholds 33,43,58 . For serological response measurement to guide clinical management of COVID-19 vaccination, further work is required to achieve harmonisation across testing platforms and to derive and validate thresholds that correlate with clinical protection.

Measurement of serological responses only offers a glimpse of the potential breadth of immune responses to COVID-19 vaccination. Both nAb and cellular responses to vaccination play complementary and vital roles in protection against COVID-19 and remain under reported 76-78 . As reported in 14% of studies, at least 18% of haematology patients achieved a positive nAb response. Positive cellular response rates were at least 15% higher than nAb responses following 1 or 2 vaccine doses. While serological responses have been utilised as surrogate endpoints in vaccination studies of immune compromised patients, more larger studies are required to identify new immune markers for vaccine response and to determine efficacy of vaccination.

There are several limitations to this review. In particular the moderate quality of findings due to significant clinical and statistical heterogeneity of included studies and the proportion of poorer quality studies. In line with other established studies of vaccination in haematology patients, only immune response data was analysed as clinical efficacy data was limited.

In conclusion, this systematic review and meta-analysis has comprehensively summarised the latest data on response to COVID-19 vaccination in patients with haematological malignancy. Overall, seropositive rates were reasonable at 67% following two doses of vaccination respectively. Higher risk patient groups were identified, namely patients with CLL and patients receiving active therapy including targeted and CD-20 monoclonal therapies. New approaches to high risk patients who are poor responders to vaccination are urgently required. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

The coronavirus is here to stay -here's what that means

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

Clinical features associated with COVID-19

Heterogeneity: I 2 = 92%, τ 2 = 0.0215, p < 0.01